AKT2 and dry age related macular degeneration: As depicted in the schematic (Fig. 8g), our findings suggest that targeting the homing of activated neutrophils into the retina by specifically inhibiting AKT2-driven inflammation is potentially a novel therapeutic approach in early, dry AMD.